Invesaro

Stocks Health care NEOG

NASDAQ · Health care

Neogen Corp (NEOG)

Neogen Corp reported revenue of $870.4M in fiscal 2026, down 2.7% from a year earlier. It posted a net loss of $7.9M. Operating cash flow minus capital spending left $31.9M of free cash flow in fiscal 2026. At May 31, 2026 it held $185.5M in cash against $793.7M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on July 30, 2026.

Revenue (FY2026)
$870.4M
-2.7% year on year
Net margin
-0.9%

What Neogen Corp does

Neogen Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker NEOG.

Revenue and profit by year

Revenue
FY19: $414.2M $414.2M FY19FY20: $418.2M $418.2M FY20FY21: $468.5M $468.5M FY21FY22: $527.2M $527.2M FY22FY23: $822.4M $822.4M FY23FY24: $924.2M $924.2M FY24FY25: $894.7M $894.7M FY25FY26: $870.4M $870.4M FY26
Net income
FY19: $60.2M $60.2M FY19FY20: $59.5M $59.5M FY20FY21: $60.9M $60.9M FY21FY22: $48.3M $48.3M FY22FY23: -$22.9M -$22.9M FY23FY24: -$9.4M -$9.4M FY24FY25: -$1.1B -$1.1B FY25FY26: -$7.9M -$7.9M FY26

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2026$870.4M-$21.6M-$7.9M-$0.04$31.9M
2025$894.7M-$1.1B-$1.1B-$5.03-$46.4M
2024$924.2M$58.6M-$9.4M-$0.04-$76.1M
2023$822.4M$37.5M-$22.9M-$0.12-$24.7M
2022$527.2M$58.6M$48.3M$0.45$43.6M
2021$468.5M$74.2M$60.9M$0.57$54.4M

Latest SEC filings

What Neogen Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 21, 2026
    Annual report to shareholders ARS
  2. August 21, 2026
    Additional proxy material DEFA14A
  3. August 21, 2026
    Proxy statement DEF 14A
  4. August 7, 2026
    Executive or director change 8-K
  5. July 30, 2026
    Annual report 10-K · period to May 31, 2026
  6. July 30, 2026
    Quarterly results 8-K
  7. July 7, 2026
    Passive stake (5% or more) SCHEDULE 13G
  8. June 25, 2026
    Employee plan annual report 11-K
  9. May 20, 2026
    Conflict minerals disclosure SD
  10. May 14, 2026
    Passive stake changed SCHEDULE 13G/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 20, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about NEOG

What does Neogen Corp do?

Neogen Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker NEOG.

Is Neogen Corp profitable?

No. In fiscal 2026 it reported a net loss of $7.9M on revenue of $870.4M.

How much revenue does Neogen Corp make?

In fiscal 2026 Neogen Corp reported revenue of $870.4M. That is 2.7% less than a year earlier.

When did Neogen Corp last report?

Its most recent periodic report is the annual report (10-K) filed on July 30, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the annual report to shareholders from August 21, 2026.

Similar companies

IDXX
Idexx Laboratories Inc
QDEL
QuidelOrtho Corp
LNTH
Lantheus Holdings, Inc.
MYGN
Myriad Genetics Inc
NTLA
Intellia Therapeutics, Inc.
TKNO
Alpha Teknova, Inc.

Follow NEOG

Get an email when Neogen Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow NEOG: get an email when it files

Where the numbers come from

Financial figures are the values Neogen Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.